Sana Biotechnology Achieves Potent In Vivo Gene Editing of Human Stem Cells Using Fusogen Technology
I'm PortAI, I can summarize articles.
Sana Biotechnology announced potent in vivo gene editing of human stem cells using fusogen technology, published in Nature Biotechnology. The study demonstrated stable gene editing in murine models, expanding applications to hematopoietic stem cells, potentially treating diseases like sickle cell disease without chemotherapy. The results highlight safer, accessible gene therapies. Published via GlobeNewswire on December 08, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments